• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Erythropoiesis-Stimulating Agents (ESAs) 11.08.07- Overview

Listen to this Podcast 

Transcript
Run Time -- 00:01:25

 

Welcome to the Food and Drug Administration's drug safety update.

I am Mandy Eisemann from F-D-A's Center for Drug Evaluation and Research.

On November 8, 2007, we issued a public health advisory about revisions to the product labeling for the erythropoiesis- [eh RITH ro POH eh sis] stimulating agents, known as E-S-As.

The advisory alerts patients and health-care providers that we have approved revised labeling for the ESAs. The revisions clarify how to safely and effectively use these products and strengthen the information about risks from using E-S-As.

The advisory applies patients taking E-S-As who have cancer or chronic kidney failure or who are taking zidovudine [zye DOE vue deen] for H-I-V.

To hear the full public health advisory, listen to part two of this Podcast.

We are asking health care professionals and patients to report serious side effects after using E-S-As to us through the MedWatch program by phone at 1-800-F-D-A-ten-88 or by the Internet at F-D-A dot G O V slash M-E-D-W-A-T-C-H.

Date created: November 8, 2007

 

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857